WHAT IS CLAIMED IS:

1. A method of increasing adeno-associated virus 9 (AAV9) vector titers in transfected producer cells grown in culture, said method comprising the steps of:
i) incubating a nucleic acid sequence that is complementary to an mRNA encoding ATP binding cassette subfamily D member 1 (ABCD1) with the cells, and
ii) transfecting an AAV9 vector comprising a nucleotide sequence encoding ABCD1 into the cells (AAV9-ABCD1 vector), wherein the amount of ABCD1 mRNA expressed from the AAV9 vector is decreased, thereby increasing AAV9-ABCD1 vector yield in cell lysate and/or media by about 1 fold to about 50 fold compared to a reference standard.

2. The method of claim 1, wherein the nucleic acid sequence that is complementary to an mRNA encoding ABCD1 is an interfering RNA.

3. The method of claim 2, wherein the wherein the interfering RNA is an shRNA or siRNA.

4. The method of claim 3, wherein the siRNA comprises SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, or a combination thereof.

5. The method of claim 1, wherein the reference standard comprises AAV9-ABCD1 vector yield in cell lysate and/or media from producer cells that were not incubated with a nucleic acid sequence that is complementary to an mRNA encoding ABCD1.

6. Use of a composition comprising purified AAV9-ABCD1 vector obtained from the producer cells of claim 1 in the manufacture of a medicament for the treatment of X-linked adrenoleukodystrophy (X-ALD).

7. The use of claim 6, wherein the composition comprising purified AAV9-ABCD1 vector is to be administered by intrathecal administration.

8. Use of an adeno-associated virus (AAV) vector encoding an ATP binding cassette subfamily D member 1 (ABCD1) in the manufacture of a medicament for the treatment of X-linked adrenoleukodystrophy (X-ALD), wherein said vector is to be administered by intrathecal administration.

9. The use of claim 8, wherein the intrathecal administration is to be mediated by an osmotic pump.

10. The use of claim 8, wherein the dose of vector is about $1x10^{13}$GC to about $10x10^{13}$GC.

11. The use of claim 8, wherein the AAV is AAV9.

12. Use of a vector encoding ABCD1 in the manufacture of a medicament for the treatment of X-linked adrenoleukodystrophy (X-ALD), wherein the treatment comprises providing ATP binding cassette subfamily D member 1 (ABCD1), wherein said vector is to be administered by intrathecal administration, and wherein ABCD1 expression from said vector in the central nervous system is less than ABCD1 expression from said vector in peripheral organs.

13. The use of claim 12, wherein ABCD1 expression from said vector in the central nervous system is about 3 fold higher than expression of ABCD1 in the central nervous system of an untreated subject that does not have X-ALD.

14. The use of claim 13, wherein the ABCD1 expression from said vector in peripheral organs is about 90% less than expression of ABCD1 in the peripheral organs of an untreated subject that does not have X-ALD.